secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001764013-25-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q3 net loss $111.1M; cash $374.7M plus $450M placement
-------------------------------------------------------------------------

- Net loss $111.1M ($0.76/sh) vs $51.4M ($0.36) y/y; R&D spend $94.5M up from $48.3M on IMVT-1402 prep.
- Pro forma cash ~$825M after $450M private placement closed Jan 15, 2025.
- Batoclimab MG pivotal and CIDP period 1 results expected by March 31, 2025.
- IMVT-1402: 6 INDs cleared; pivotal GD and D2T RA studies enrolling with autoinjector.
- Batoclimab GD additional data (6-month remission) summer 2025; TED top-line H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/0001764013-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/imvt-20250206.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer